# Clinical Trials Data KRAS - Document 24

# Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC

## Clinical Trial: https://clinicaltrials.gov/study/NCT02039336

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histological or cytological proof of advanced non-small cell lung cancer\n\* Written documentation of KRAS (exon 2, 3 or 4) mutation\n\* At least 18 years of age or older\n\* Able and willing to give written informed consent\n\* WHO performance status of 0 or 1\n\nExclusion Criteria:\n\n\* Symptomatic or untreated leptomeningeal disease\n\* Symptomatic brain metastasis\n\* Impairment of gastrointestinal function\n\* Uncontrolled infectious disease\n\* Left ventricular ejection fraction \\< 50%\n\* Retinal degenerative disease or with history of uveitis, retinal vein occlusion or retinal detachment\n\nOther protocol-defined inclusion/exclusion criteria may apply",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial eligibility criteria, a patient with a KRAS gene mutation would be eligible for this clinical trial, provided they meet all the other inclusion criteria and none of the exclusion criteria. Specifically, one of the inclusion criteria is "Written documentation of KRAS (exon 2, 3 or 4) mutation," which implies that having a KRAS mutation is a requirement for participation.   
  
To be eligible, the patient must also:  
  
- Have histological or cytological proof of advanced non-small cell lung cancer.  
- Be at least 18 years of age or older.  
- Be able and willing to give written informed consent.  
- Have a WHO performance status of 0 or 1.  
  
Additionally, they must not have any of the exclusion criteria such as symptomatic or untreated leptomeningeal disease, symptomatic brain metastasis, impairment of gastrointestinal function, uncontrolled infectious disease, left ventricular ejection fraction under 50%, or a retinal degenerative disease including any history of uveitis, retinal vein occlusion, or retinal detachment. Other protocol-defined criteria might also apply.